Pink Sheet is part of the Business Intelligence Division of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

Zetia/Zocor combo is Vytorin

Executive Summary

Merck and Schering-Plough choose Vytorin as the brand name for the fixed-dose ezetimibe/simvastatin combination. Companies filed for approval of Zetia/Zocor for cholesterol reduction in July 2003; the user fee deadline is Sept. 24, 2004. Zetia was approved in 2002 for use as monotherapy and in combination with Zocor (1"The Pink Sheet" Nov. 4, 2002, p. 5)...
Advertisement

Related Content

Merck/Schering Vytorin (correction)
Schering/Merck Zetia Clears FDA; Price Favors Combo With Low-Dose Zocor
Schering/Merck Zetia Clears FDA; Price Favors Combo With Low-Dose Zocor
Advertisement
UsernamePublicRestriction

Register

PS043548

Ask The Analyst

Please Note: You can also Click below Link for Ask the Analyst
Ask The Analyst

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel